Daptomycin

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Monday, September 13, 2021 - 2:48pm

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Monday, September 13, 2021 - 1:03pm

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity

Monday, July 19, 2021 - 12:30pm

The analysis of bone samples demonstrated that CF-296 has potent anti-staphylococcal activity and, when used with daptomycin, is active and well tolerated in MRSA acute osteomyelitis.

Key Points: 
  • The analysis of bone samples demonstrated that CF-296 has potent anti-staphylococcal activity and, when used with daptomycin, is active and well tolerated in MRSA acute osteomyelitis.
  • Of note, the addition of CF-296 to both daptomycin or vancomycin resulted in significantly enhanced antibacterial activity in the model, relative to the activity of these standard-of-care antibiotics alone.
  • ContraFect continues to evaluate CF-296 in further preclinical studies and the potential for future clinical development.
  • CF-296 was developed by ContraFect and the Company is actively pursuing global rights to this investigational development candidate.

Dr. Reddy’s Q3 & 9M FY21 Financial Results

Friday, January 29, 2021 - 9:37am

This included Cinacalcet Tablets, Sapropterin Dihydrochloride Tablets and Succinylcholine Chloride Injection in the US along with Daptomycin Injection in Canada.

Key Points: 
  • This included Cinacalcet Tablets, Sapropterin Dihydrochloride Tablets and Succinylcholine Chloride Injection in the US along with Daptomycin Injection in Canada.
  • As of 31st December 2020, cumulatively 89 generic filings are pending for approval with the USFDA (87 ANDAs and 2 NDAs under 505(b)(2) route).
  • Of the 89 ANDAs, 48 are Para IVs and we believe 24 have First to File status.
  • As % to revenues these are: Q3 FY21: 8.3% | Q2 FY 21: 8.9% | Q3 FY20: 9.0%.

Sandoz acquires US distribution rights to two key hospital injectable medicines, reinforcing strategic focus on key growth segment

Monday, March 23, 2020 - 8:01pm

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

Key Points: 
  • This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.
  • Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties.
  • Neither can there be any guarantee that the daptomycin or fosaprepitant products will be commercially successful in the future.
  • Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.

Cubicin: 2019 Drug Insight Report with Sales Forecasting to 2021 - ResearchAndMarkets.com

Tuesday, November 12, 2019 - 10:30am

The "Cubicin - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cubicin - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Cubicin Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with their location.
  • The report covers the Global Market Assessment of Cubicin, covering the historical global sales and also provides the Cubicin sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Cubicin and emerging therapies in this space.

Innovation Pharmaceuticals Highlights Preclinical Data by Independent Cancer Researchers Supporting p53 Drug Candidate Kevetrin’s Potential in Treating Acute Myeloid Leukemia

Monday, October 28, 2019 - 1:30pm

Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS).Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019.

Key Points: 
  • Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS).Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019.
  • A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection.
  • The Company has in some cases identified forward-looking statements by using words such as anticipates, believes, hopes, estimates, looks, expects, plans, intends, goal, potential, may, suggest, and similar expressions.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.

Cipla Announces the Launch of Daptomycin for Injection, 500 mg/vial, Single-dose Vials (for Intravenous use only)

Thursday, September 26, 2019 - 12:00pm

According to IQVIA (IMS Health), Cubicin for Injection (daptomycin for injection) had U.S. sales of approximately $606 Million for the 12-month period ending June 2019.

Key Points: 
  • According to IQVIA (IMS Health), Cubicin for Injection (daptomycin for injection) had U.S. sales of approximately $606 Million for the 12-month period ending June 2019.
  • Cipla USA, Inc., is a wholly-owned subsidiary of Cipla Limited representing its direct market presence in the U.S. and focused on marketing the highest quality pharmaceutical products in the retail and institutional spaces in the country.
  • Cipla USA, Inc. is headquartered in Warren, New Jersey, and is today among the most dispensed generic players by prescription.
  • Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets.

Dr. Reddy’s Q1 FY20 Financial Results

Monday, July 29, 2019 - 2:15pm

We launched five new products (Daptomycin, Testosterone gel, Tobramycin, Vitamin K & OTC calcium carbonate) and re-launched Isotretinoin during the quarter.

Key Points: 
  • We launched five new products (Daptomycin, Testosterone gel, Tobramycin, Vitamin K & OTC calcium carbonate) and re-launched Isotretinoin during the quarter.
  • Of these 104 ANDAs, 58 are Para IVs out of which we believe 34 have First to File status.
  • As % to Revenues- Q1 FY20: 9.4% | Q4 FY 19: 9.1% | Q1 FY19: 11.2%.
  • With effect from August 1, 2019, Erez Israeli will be elevated as Chief Executive Officer (CEO) of Dr. Reddys Laboratories Limited.

Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market

Wednesday, May 15, 2019 - 6:59am

The Cubicin for Injection (daptomycin for injection) brand and generic had U.S. sales of approximately $640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health*.

Key Points: 
  • The Cubicin for Injection (daptomycin for injection) brand and generic had U.S. sales of approximately $640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health*.
  • Dr. Reddys Daptomycin for Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin.
  • Cubicin is a trademark of Merck Sharp & Dohme Corp.
    About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.